ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO131

Differential Epidemiology of Prostate Cancer Specific Mortality for Black Men With ESKD

Session Information

Category: Onconephrology

  • 1600 Onconephrology

Authors

  • Manvar, Sohilkumar, University Hospitals, Cleveland, Ohio, United States
  • Dong, Weichuan, Case Western Reserve University, Cleveland, Ohio, United States
  • Koroukian, Siran M., Case Western Reserve University, Cleveland, Ohio, United States
  • Sarabu, Nagaraju, University Hospitals, Cleveland, Ohio, United States
Background

Studies exploring racial disparity in mortality among ESKD patients with prostate cancer (PCa) are limited.

Methods

We used Surveillance, Epidemiology and End Results data linked to Medicare to identify men (age >40) diagnosed with PCa years 2004-2015. After excluding patients with missing data, we categorized participants into ESKD (dialysis + kidney transplant) and non-ESKD by using international classification of disease, 9th revision, clinical modification. We compared overall and PCa specific mortality among Blacks, Whites, Hispanics and others using Cox proportional hazards and Fine and Gray competing risk models respectively.

Results

We included 18282 Blacks, 107457 Whites, 2397 Hispanics, and 6785 others for analysis. Blacks were five times more likely to having ESKD, more likely to present with metastatic disease, younger, had similar Gleason Score, more likely to be single, and live in higher poverty areas than Whites (Figure 1). Compared to Whites, Blacks had similar all-cause mortality (Hazard Ratio (HR): 0.80.91.1) and PCa mortality (HR: 0.40.61.0) in ESKD group while they had higher all-cause (HR: 1.11.21.2) and PCa mortality (HR: 1.11.21.3) in non-ESKD group (Figure 2).

Conclusion

ESKD and prostate cancer are more common among Blacks than Whites. Despite presenting with higher metastatic disease, prostate cancer mortality for Blacks with ESKD is similar but higher for those without ESKD than Whites. Future research should focus on understanding these racial differences.

Figure 1: Baseline Characteristics

Figure 2: Kaplan Meier Survival Curves for Prostate Cancer Mortality, Stratified by Race and ESKD status.